These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9513400)

  • 21. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
    Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
    Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pancreatic cancer screening: mission impossible?].
    Bartel M; Friess H
    Z Gastroenterol; 2006 Nov; 44(11):1181-2. PubMed ID: 17115361
    [No Abstract]   [Full Text] [Related]  

  • 23. [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma].
    Zhang Y; Ji SR; Feng DX; Ji J; Han TQ
    Ai Zheng; 2003 Mar; 22(3):295-7. PubMed ID: 12654190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CA19-9].
    Odagiri E
    Nihon Rinsho; 1999 Dec; 57 Suppl():459-61. PubMed ID: 10778164
    [No Abstract]   [Full Text] [Related]  

  • 26. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of CA 19-9 serum course in pancreatic cancer.
    Safi F; Schlosser W; Falkenreck S; Beger HG
    Hepatogastroenterology; 1998; 45(19):253-9. PubMed ID: 9496523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CA19-9 serum concentrations--analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival.
    Klapdor R; Bahlo M; Babinski A; Klapdor S
    Anticancer Res; 2010 May; 30(5):1869-74. PubMed ID: 20592394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer.
    Wu Z; Kuntz AI; Wadleigh RG
    Clin Adv Hematol Oncol; 2013 Jan; 11(1):50-2. PubMed ID: 23416865
    [No Abstract]   [Full Text] [Related]  

  • 30. Is CA 19-9 useful in the management of pancreatic cancer?
    Balzano G; Di Carlo V
    Lancet Oncol; 2008 Feb; 9(2):89-91. PubMed ID: 18237847
    [No Abstract]   [Full Text] [Related]  

  • 31. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
    Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
    Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study on the expression of the blood group antigens Le(a), Le(b), Le(x), Le(y) and the carbohydrate antigens CA19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma.
    Makovitzky J; Schwenk J
    Acta Histochem Suppl; 1990; 40():143-6. PubMed ID: 2091042
    [No Abstract]   [Full Text] [Related]  

  • 33. Identifying markers for pancreatic cancer by gene expression analysis.
    Zhou W; Sokoll LJ; Bruzek DJ; Zhang L; Velculescu VE; Goldin SB; Hruban RH; Kern SE; Hamilton SR; Chan DW; Vogelstein B; Kinzler KW
    Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):109-12. PubMed ID: 9488584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
    Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
    Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical significance of 2-6 sialyl Le(a) antigen assay as a tumor marker].
    Kannagi R; Itai S; Harada R
    Nihon Rinsho; 1990 Feb; 48 Suppl():1045-52. PubMed ID: 2355503
    [No Abstract]   [Full Text] [Related]  

  • 37. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.
    Narimatsu H; Iwasaki H; Nakayama F; Ikehara Y; Kudo T; Nishihara S; Sugano K; Okura H; Fujita S; Hirohashi S
    Cancer Res; 1998 Feb; 58(3):512-8. PubMed ID: 9458099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type.
    Pour PM; Tempero MM; Takasaki H; Uchida E; Takiyama Y; Burnett DA; Steplewski Z
    Cancer Res; 1988 Oct; 48(19):5422-6. PubMed ID: 3166398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A resected case of intralobar pulmonary sequestration with increased serum tumor markers, CA19-9, CA125 and NCC-ST-439].
    Nakamura H; Katsumi T; Nagata S; Saito M; Konaka C; Kato H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Dec; 35(12):1425-29. PubMed ID: 9567093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
    Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
    Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.